陈光伟教授治疗中晚期肝癌经验

陈光伟教授从事中西医结合肿瘤防治工作30余年,积累了丰富的临床经验,尤其对中晚期肝癌的治疗有独到之处,认为中晚期肝癌为肝瘀血聚,脾肾亏虚,正虚邪盛;治疗时应重视健脾益肾,养肝化瘀,扶正抗邪,体现"扶正抗癌"的法则并自拟扶正抗癌汤和扶正抗癌丸,以起到祛邪不伤正,扶正以祛邪的治疗效果。

阿帕替尼联合肝动脉化疗栓塞术治疗中晚期肝癌的临床疗效及安全性评价

肝癌进展迅速、侵袭性强、恶化程度高,严重威胁患者的生命安全。为控制肝癌进展,提高患者生存率,需予以及时有效的临床干预。本文回顾性分析阿帕替尼与肝动脉化疗栓塞术联合治疗中晚期肝癌的临床疗效及安全性,现报告如下。

肝动脉插管化疗栓塞术在中晚期肝癌治疗中的应用

对226例中晚期肝癌患者采用肝动脉插管、灌注化疗和栓塞治疗,共524次。治疗1次后失访82例,另184例治疗2次或以上后,取得较好疗效。该组病例术后3个月、6个月、9个月和1年以上生存率分别为100%、8162%、59.8%、42.0%。结果表明,肝动脉化疗栓塞术治疗中晚期肝癌疗效显著。

靶向联合免疫治疗在中晚期原发性肝癌治疗中的临床应用分析

靶向联合免疫治疗在中晚期原发性肝癌治疗中的临床应用分析。方法 对收入的中晚期原发性肝癌患者进行治疗干预,对照组接受仑伐替尼靶向治疗;治疗,观察组接受仑伐替尼靶向治疗联合信迪利单抗免疫治疗,对比治疗结果。结果 较对照组,观察组的治疗总有效率更高且治疗后患者的肝脏生化指标显著改善、癌标志物水平减低,患者的生活质量显著提升,对比有统计学意义。结论 靶向治疗联合免疫治疗方式可以有效应对中晚期原发性肝癌患者疾病,患者治疗后的总有效率高且患者的生活质量显著降低,可推广。

Study of hepatic arterial infusion of Endostar combined with TACE on advanced hepatocellular carcinoma

Objective:To study the efficacy and safety of hepatic arterial infusion of Endostatin(YH-16,Endostar),combined with transcatheter arterial chemoembolization(TACE) on advanced hepatocellular carcinoma.Methods:Thirty patients with advanced hepatocellular carcinoma were enrolled in the study.The patients received hepatic arterial infusion of Endostar combined with TACE.The efficacy was evaluated strictly after 1-2 cycles according to RECIST criteria and the value of AFP;quality of life(QOL) was evaluated according to Karnofsky scores.Adverse effects were evaluated too.Results:29 cases' efficacy was evaluated among the total 30 cases.The KPS were significantly increased after the treatment(80.39 ± 8.37 vs 73.93 ± 9.22,P = 0.002).Compared with control group,the objective response rate(CR and PR) and the rate of AFP negative changed were significantly higher(P = 0.021,P = 0.046).The adverse effects were not obvious.Conclusion:The QOL and preliminary efficiency of patients of advanced hepatocellular carcinoma may be improved by hepatic arterial infusion of Endostar combined with TACE,the rate of AFP negative changed were significantly higher too,and there are little of adverse effects.It is worthy to clinical generalization and further clinical observation.